Salmedix

Founded in 2000 by David Kabakoff, Salmedix is a pioneer in oncology drug development, focusing on treatments for hematologic malignancies. The company's primary product, SDX-105, has been made available in Germany to address various blood cancers, and is currently undergoing Phase II clinical trials in the U.S. and Canada. Additionally, Salmedix has other clinical-stage product candidates, SDX-101 and SDX-102, which are in Phase II development, backed by substantial prior human clinical experience. The recent $45.00M Series C investment received on 19 October 2005 included prominent investors such as Novo Holdings, OrbiMed, H.I.G. Capital, Quilvest Capital Partners, Covera Ventures, and Cariden Technologies. The company's slogan, "Pioneering advanced treatments for blood cancers, delivering innovative Phase II clinical trials with a focus on patient health and care," embodies its commitment to revolutionizing the field of oncology and prioritizing patient well-being and care. With its base in San Diego, California, Salmedix is carving a niche for itself in the Biotechnology and Health Care industries.